🚀 VC round data is live in beta, check it out!
Kelun-Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kelun-Biotech and similar public comparables like Akeso, BridgeBio Pharma, Summit Therapeutics, Elanco and more.
Kelun-Biotech Overview
About Kelun-Biotech
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Founded
2016
HQ
Employees
1.9K
Website
Sectors
Financials (LTM)
EV
$12B
Kelun-Biotech Financials
Kelun-Biotech reported last 12-month revenue of $314M and negative EBITDA of ($34M).
In the same LTM period, Kelun-Biotech generated $244M in gross profit, ($34M) in EBITDA losses, and had net loss of ($56M).
Revenue (LTM)
Kelun-Biotech P&L
In the most recent fiscal year, Kelun-Biotech reported revenue of $280M and EBITDA of ($7M).
Kelun-Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $314M | XXX | $280M | XXX | XXX | XXX |
| Gross Profit | $244M | XXX | $185M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | ($34M) | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | (11%) | XXX | (3%) | XXX | XXX | XXX |
| EBIT Margin | (16%) | XXX | (7%) | XXX | XXX | XXX |
| Net Profit | ($56M) | XXX | ($37M) | XXX | XXX | XXX |
| Net Margin | (18%) | XXX | (13%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kelun-Biotech Stock Performance
Kelun-Biotech has current market cap of $12B, and enterprise value of $12B.
Market Cap Evolution
Kelun-Biotech's stock price is $53.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12B | $12B | 0.1% | XXX | XXX | XXX | $-0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKelun-Biotech Valuation Multiples
Kelun-Biotech trades at 37.6x EV/Revenue multiple, and (350.4x) EV/EBITDA.
EV / Revenue (LTM)
Kelun-Biotech Financial Valuation Multiples
As of March 11, 2026, Kelun-Biotech has market cap of $12B and EV of $12B.
Equity research analysts estimate Kelun-Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kelun-Biotech has a P/E ratio of (222.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12B | XXX | $12B | XXX | XXX | XXX |
| EV (current) | $12B | XXX | $12B | XXX | XXX | XXX |
| EV/Revenue | 37.6x | XXX | 42.1x | XXX | XXX | XXX |
| EV/EBITDA | (350.4x) | XXX | (1716.9x) | XXX | XXX | XXX |
| EV/EBIT | (241.3x) | XXX | (597.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 48.3x | XXX | 63.8x | XXX | XXX | XXX |
| P/E | (222.5x) | XXX | (338.4x) | XXX | XXX | XXX |
| EV/FCF | (251.0x) | XXX | (159.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kelun-Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kelun-Biotech Margins & Growth Rates
Kelun-Biotech's revenue in the last 12 month grew by 60%.
Kelun-Biotech's revenue per employee in the last FY averaged $0.2M.
Kelun-Biotech's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kelun-Biotech's rule of X is 139% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kelun-Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 60% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | (11%) | XXX | (3%) | XXX | XXX | XXX |
| EBITDA Growth | (289%) | XXX | 630% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 139% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 25% | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 60% | XXX | 62% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 77% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kelun-Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Akeso | XXX | XXX | XXX | XXX | XXX | XXX |
| BridgeBio Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Summit Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Elanco | XXX | XXX | XXX | XXX | XXX | XXX |
| Regencell Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kelun-Biotech M&A Activity
Kelun-Biotech acquired XXX companies to date.
Last acquisition by Kelun-Biotech was on XXXXXXXX, XXXXX. Kelun-Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kelun-Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKelun-Biotech Investment Activity
Kelun-Biotech invested in XXX companies to date.
Kelun-Biotech made its latest investment on XXXXXXXX, XXXXX. Kelun-Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kelun-Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kelun-Biotech
| When was Kelun-Biotech founded? | Kelun-Biotech was founded in 2016. |
| Where is Kelun-Biotech headquartered? | Kelun-Biotech is headquartered in United States. |
| How many employees does Kelun-Biotech have? | As of today, Kelun-Biotech has over 1K employees. |
| Is Kelun-Biotech publicly listed? | Yes, Kelun-Biotech is a public company listed on HKEX. |
| What is the stock symbol of Kelun-Biotech? | Kelun-Biotech trades under 06990 ticker. |
| When did Kelun-Biotech go public? | Kelun-Biotech went public in 2023. |
| Who are competitors of Kelun-Biotech? | Kelun-Biotech main competitors are Akeso, BridgeBio Pharma, Summit Therapeutics, Elanco. |
| What is the current market cap of Kelun-Biotech? | Kelun-Biotech's current market cap is $12B. |
| What is the current revenue of Kelun-Biotech? | Kelun-Biotech's last 12 months revenue is $314M. |
| What is the current revenue growth of Kelun-Biotech? | Kelun-Biotech revenue growth (NTM/LTM) is 60%. |
| What is the current EV/Revenue multiple of Kelun-Biotech? | Current revenue multiple of Kelun-Biotech is 37.6x. |
| Is Kelun-Biotech profitable? | No, Kelun-Biotech is not profitable. |
| What is the current EBITDA of Kelun-Biotech? | Kelun-Biotech has negative EBITDA and is not profitable. |
| What is Kelun-Biotech's EBITDA margin? | Kelun-Biotech's last 12 months EBITDA margin is (11%). |
| What is the current EV/EBITDA multiple of Kelun-Biotech? | Current EBITDA multiple of Kelun-Biotech is (350.4x). |
| What is the current FCF of Kelun-Biotech? | Kelun-Biotech's last 12 months FCF is ($47M). |
| What is Kelun-Biotech's FCF margin? | Kelun-Biotech's last 12 months FCF margin is (15%). |
| What is the current EV/FCF multiple of Kelun-Biotech? | Current FCF multiple of Kelun-Biotech is (251.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.